Bristol-Myers Squibb Co. under the ticker symbol BMY. Here is some more information that we have about Bristol-Myers Squibb Co.

Get our alerts and future stock picks in your email inbox

What you feel with this company ? Are you willing to
Bristol-Myers Squibb Co.

Bristol-Myers Squibb Company (BMS) engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of pharmaceuticals and nutritional products worldwide. It operates in two segments, Pharmaceuticals and Nutritionals. The Pharmaceuticals segment offers cardiovascular products, including PLAVIX, AVAPRO/AVALIDE, and PRAVACHOL; virology products comprising REYATAZ, SUSTIVA, and BARACLUDE; oncology products comprising ERBITUX, TAXOL, SPRYCEL, and IXEMPRA; affective and other psychiatric disorder products, such as ABILIFY; immunoscience products comprising ORENCIA; and other pharmaceutical products that include EFFERALGAN, ASPIRINE UPSA, DAFALGAN, and FERVEX. It sells its pharmaceutical products to wholesalers, distributors, retailers, hospitals, clinics, government agencies, and pharmacies. The Nutritionals segment manufactures, markets, distributes, and sells infant formulas and other nutritional products comprising ENFAMIL products that contain nutrients, such as docosahexaenoic and arachidonic acids. The company is also developing various compounds, which are in phase III clinical trials, including Apixaban, Saxagliptin, Dapagliflozin, Ipilimumab, Belatacept, XL-184, Tanespimycin, and Brivanib. In addition, it develops a therapeutic class of biologics called ADNECTINS. BMS has agreements with Sanofi-Aventis; Otsuka Pharmaceutical Co., Ltd.; ImClone Systems Incorporated; Gilead Sciences, Inc.; Medarex, Inc.; and AstraZeneca PLC, as well as collaborations with Pfizer Inc.; Exelixis, Inc.; and KineMed Inc. It also has an agreement with PDL BioPharma, Inc. for the development and commercialization of anti-CS1 antibody and elotuzumab for multiple myeloma; and a strategic alliance with Ensemble Discovery Corporation. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.
28,000 Employees
Last Reported Date: 02/14/14
Founded in 1887
Last $62.07 USD
Change Today -0.02 / -0.03%
Volume 3.7M
As of 8:04 PM 01/23/15 All times are local (Market data is delayed by at least 15 minutes).

bristol-myers squibb co (BMY) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/12/15 - $64.44
52 Week Low
06/5/14 - $46.30
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Request Investor Kit
BMY:US Advanced Stock Chart

bristol-myers squibb co (BMY) Related Bloomberg News

Fed, U.S. GDP, Greek Vote, Apple, Amazon: Week Ahead Jan. 24-31
Stakes High for AstraZeneca Heart Drug Facing Tough Competition
Pfizer to Skip Melanoma in Bid to Join Cancer Race
Bristol-Myers Shares Gain as Lung Cancer Study Ended Early
Bristol-Myers Drug Wins U.S. Approval to Treat Advanced Melanoma

bristol-myers squibb co (BMY) Related News

Company News: Alstom, GE, American Apparel, Bristol-Myers Squibb, Airbus, Starbucks, Square
Prudential Piles on the Corporate Pensions
White-Collar Workers Live Longer and the Gap Is Widening
What's the Dollar Value of Online Patient Chatter?

bristol-myers squibb co (BMY) Key Developments

Bristol-Myers Squibb Company Announces Executive Changes, Effective May 5

Bristol-Myers Squibb Company announced a number of leadership changes approved by its board of directors and effective at the close of the annual shareholders' meeting on May 5. Giovanni Caforio, M.D., 50, will become chief executive officer of the company. Lamberto Andreotti, 64, will become executive chairman of the board of directors on May 5 and will continue to serve as chairman after his retirement on August 3. James M. Cornelius, 71, has chosen not to stand for re-election as non-executive chairman and will retire from the board. TogoD. West, Jr., 72, will become the lead independent director on the company's board. Caforio brings a broad range of experience to his role as CEO. Through ever-expanding roles, Caforio has made significant contributions to improving the company's strategic focus and operational performance. He helped build the company's leadership in immuno-oncology through his roles in U.S. and Global Oncology. As chief commercial officer and chief operating officer he led the transformation of the company's global commercial organization into one uniquely designed to be able to differentially invest in the most important opportunities. As a member of the company's Senior Management Team since 2011 and the company's board of directors since 2014, Caforio has been integral in shaping the company's successful transformation to a Diversified Specialty BioPharma company. Andreotti joined Bristol-Myers Squibb in 1998 as vice president and general manager, Italy and European Oncology. He held a number of roles of increasing responsibility and was elected to the board of directors in March 2009. He became CEO in May 2010. He also sits on the board of directors of E. I. du Pont de Nemours and Company. Cornelius has been non-executive chairman since May 2010. He served as chairman and chief executive officer from February 2008 to May 2010 and served as chief executive officer from September 2006 to February 2008. Cornelius is the non-executive chairman of the board of directors of Mead Johnson Nutrition Company.

Bristol-Myers Squibb Company and Eli Lilly and Company Agree to Clinical Trial Collaboration

Bristol-Myers Squibb Company (BMY) and Eli Lilly and Company (LLY) have agreed to a clinical trial collaboration to evaluate the safety, tolerability and preliminary efficacy of Bristol-Myers Squibb's immunotherapy Opdivo in combination with Lilly's galunisertib as a potential treatment option for patients with advanced glioblastoma, hepatocellular carcinoma and non-small cell lung cancer. The study will be conducted by LLY.

The Department of Justice and the U.S. Environmental Protection Agency Proposes Settlement with Pechiney Plastic Packaging, Inc., Albea Americas, Inc., Bristol-Myers Squibb Company, Citigroup Inc., and Rexam Beverage Can Company

The Department of Justice and the U.S. Environmental Protection Agency (EPA) announced a proposed settlement with several companies to address the Pohatcong Valley Groundwater Contamination Superfund site in Warren County, New Jersey. The companies are Pechiney Plastic Packaging, Inc. (Pechiney), Albea Americas, Inc., Bristol-Myers Squibb Company, Citigroup Inc., and Rexam Beverage Can Company. The Pohatcong site is contaminated with trichloroethylene (TCE) and perchloroethylene (PCE), which can have serious health effects. Under the proposed settlement, Pechiney will have primary responsibility for cleaning up contaminated soil and groundwater at the site, connecting some residents to public water to avoid contaminated groundwater, and operating systems to capture vapors that are getting into a manufacturing facility. As a precaution, the company will continue to monitor for vapor intrusion into homes at the site. In addition, the EPA will receive an estimated $29.5 million for certain past costs and be paid for its future oversight costs at the site. Pechiney will also perform current and future cleanup work estimated to cost $62.5 million, and will pay EPA's future oversight costs. As part of the settlement, EPA will recover civil penalties from Pechiney to resolve allegations that Pechiney violated a previous EPA order by failing to make satisfactory progress on a portion of the cleanup at the site. Pechiney will pay a cash penalty of $282,000. Pechiney will also restore and preserve approximately 60 acres of land, valued at $1.1 million, in Warren County through a Supplemental Environmental Project. This land will be converted to native grassland and will become part of the Morris Canal Greenway.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BMY:US $62.07 USD -0.02

BMY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AbbVie Inc $62.43 USD -0.55
Biogen Idec Inc $357.53 USD +3.88
Celgene Corp $123.89 USD +0.18
Novo Nordisk A/S kr293.00 DKK +4.90
Thermo Fisher Scientific Inc $124.87 USD -2.13

Industry Analysis


Industry Average

Valuation BMY Industry Range
Price/Earnings 38.1x
Price/Sales 6.4x
Price/Book 6.8x
Price/Cash Flow 37.9x
TEV/Sales 5.5x

Sponsored Financial Commentaries

Sponsored Links

Bristol-Myers Squibb to Announce Results for Fourth Quarter, Full Year 2014 on January 27
[at noodls] - NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) will announce results for the fourth quarter and full year of 2014 on Tuesday, January 27, 2015. During a conference call at 9 a.m. EST ...
Ono Pharmaceutical, Bristol-Myers Squibb and Kyowa Hakko Kirin Announce Immuno-Oncology Clinical Collaboration Studying Opdivo
[at noodls] - TOKYO & OSAKA, Japan & NEW YORK--(BUSINESS WIRE)--Ono Pharmaceutical Co.,Ltd. (Tokyo: 4528), Bristol-Myers Squibb Company(NYSE:BMY) and Kyowa Hakko Kirin Co., Ltd. (Tokyo: 4151,"Kyowa Hakko Kirin") ...
Bristol-Myers Squibb Announces Dividend
[at noodls] - NEW YORK--(BUSINESS WIRE)--The Board of Directors of Bristol-Myers Squibb Company (NYSE:BMY) today declared a quarterly dividend of thirty-seven cents ($0.37) per share on the $.10 par value Common Stock ...
US sues Deutsche in $190m taxes claim
[at Financial Times] - Deutsche Bank and other firms are being pursued for more than $190m over allegedly setting up shell companies to avoid paying US taxes in 2000, according to a lawsuit filed Monday by the US attorney for ...
Bristol-Myers Posts Positive Opdivo Hodgkin Lymphoma Data
Anticoagulant Effect of Eliquis
[at noodls] - Dateline: PRINCETON, N.J. & NEW YORK "The Bristol-Myers Squibb and Pfizer alliance remains committed to delivering important treatment options to patients and physicians and is pleased with the positive ...
Two Cancer Drugs for Hodgkin Lymphoma Shown Effective
[at The Wall Street Journal] - Two cancer immunotherapy drugs being developed by Bristol-Myers and Merck proved remarkably effective against the blood cancer Hodgkin lymphoma in two small, separate studies, researchers said.
What’s News: Business & Finance
[at The Wall Street Journal] - What’s News: Business & Finance
[Business Wire] - Bristol-Myers Squibb Company today announced positive results from a cohort of patients in its ongoing Phase 1b trial which evaluated PD-1 immune checkpoint inhibitor, Opdivo , in patients with relapsed or refractory hematological malignancies .